Sugi Predict

Sugi Predict / Compounds / SCHEMBL28611486

SCHEMBL28611486

SCHEMBL28611486

CCC(C(=O)O)c1cc(C)no1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 1/20 0.47
▸ PPARG P37231 1/20 0.43
▸ PPARA Q07869 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ VHL P40337 2/20 0.41
▸ LMNA P02545 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ AKR1C3 P42330 5/20 0.36
▸ AKR1C2 P52895 5/20 0.36
▸ AKR1C1 Q04828 1/20 0.36
▸ PTGS1 P23219 1/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ EPHX2 P34913 1/20 0.35
▸ GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28623109 0.86 HCAR2 (0.44) HCAR2PPARGPPARAALDH1A1SMN1; SMN2
SCHEMBL30179086 0.83 PPARA (0.42) HCAR2PPARGPPARAALDH1A1SMN1; SMN2
SCHEMBL21876747 0.81 HCAR2 (0.43) HCAR2PPARGPPARAALDH1A1SMN1; SMN2
SCHEMBL16619623 0.81 SMN1; SMN2 (0.43) HCAR2ALDH1A1SMN1; SMN2POLBNPC1
SCHEMBL434029 0.76 HCAR2 (0.52) HCAR2ALDH1A1SMN1; SMN2POLBNPC1
SCHEMBL21458463 0.74 PPARG (0.36) HCAR2PPARGPPARAALDH1A1SMN1; SMN2
SCHEMBL21458717 0.74 PPARG (0.36) HCAR2PPARGPPARAALDH1A1SMN1; SMN2
SCHEMBL7450688 0.73 LMNA (0.41) HCAR2ALDH1A1SMN1; SMN2POLBNPC1
SCHEMBL21009819 0.73 ALDH1A1 (0.40) HCAR2ALDH1A1SMN1; SMN2POLBNPC1
SCHEMBL5789095 0.73 ALDH1A1 (0.40) HCAR2ALDH1A1SMN1; SMN2POLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES UNIV YALE (US) 2026-04-30 — — US disclosed
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES YALE UNIVERSITY 2023-01-05 — — US disclosed
CN-113164775-A Polycyclic compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides 阿尔维纳斯运营股份有限公司 2021-07-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, ARAF, VHL HCAR2 3032/4885PPARG 4262/4885PPARA 4259/4885
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, VHL, ADRM1 HCAR2 3288/4885PPARG 4368/4885PPARA 4229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.